Hidradenitis Suppurativa
Immunology 2 original drugsImmunology indication. Hidradenitis Suppurativa has 2 FDA-approved novel treatments, led by AbbVie, with 51 active industry clinical trials across 4 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Hidradenitis Suppurativa Market Leaders
Companies with the most FDA-approved novel Hidradenitis Suppurativa drugs.
Phase 3 Readouts Pro
10 active Phase 3 trials with confidence-graded completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Hidradenitis Suppurativa Treatments by Mechanism
Top 6 mechanisms across 10 industry trials with a known mechanism of action.
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Hidradenitis Suppurativa Clinical Pipeline by Phase
75 industry-sponsored trials across 36 sponsors
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Hidradenitis Suppurativa
Novel Hidradenitis Suppurativa Drugs by Company (New molecular entities)
2 companies have an FDA-approved novel drug for Hidradenitis Suppurativa.
Hidradenitis Suppurativa Drug Targets
Molecular targets of approved and investigational Hidradenitis Suppurativa drugs — 4 targets tracked.
Biosimilars (10 BLA approved) Click to expand
Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs